98 related articles for article (PubMed ID: 19505802)
1. In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.
Sharma A; Sharma S; Khuller GK; Kanwar AJ
Int J Antimicrob Agents; 2009 Sep; 34(3):226-30. PubMed ID: 19505802
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.
Sharma A; Khuller GK; Kanwar AJ; Sharma S
J Infect; 2010 Jun; 60(6):498-501. PubMed ID: 20346970
[No Abstract] [Full Text] [Related]
3. Peptide deformylase inhibitors as potent antimycobacterial agents.
Teo JW; Thayalan P; Beer D; Yap AS; Nanjundappa M; Ngew X; Duraiswamy J; Liung S; Dartois V; Schreiber M; Hasan S; Cynamon M; Ryder NS; Yang X; Weidmann B; Bracken K; Dick T; Mukherjee K
Antimicrob Agents Chemother; 2006 Nov; 50(11):3665-73. PubMed ID: 16966397
[TBL] [Abstract][Full Text] [Related]
4. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
5. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2005 Oct; 251(1):19-22. PubMed ID: 16143463
[TBL] [Abstract][Full Text] [Related]
6. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
Cynamon M; Sklaney MR; Shoen C
J Antimicrob Chemother; 2007 Aug; 60(2):429-32. PubMed ID: 17561504
[TBL] [Abstract][Full Text] [Related]
7. Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results.
Pichota A; Duraiswamy J; Yin Z; Keller TH; Alam J; Liung S; Lee G; Ding M; Wang G; Chan WL; Schreiber M; Ma I; Beer D; Ngew X; Mukherjee K; Nanjundappa M; Teo JW; Thayalan P; Yap A; Dick T; Meng W; Xu M; Koehn J; Pan SH; Clark K; Xie X; Shoen C; Cynamon M
Bioorg Med Chem Lett; 2008 Dec; 18(24):6568-72. PubMed ID: 19008098
[TBL] [Abstract][Full Text] [Related]
8. BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis.
Cynamon MH; Alvirez-Freites E; Yeo AE
J Antimicrob Chemother; 2004 Feb; 53(2):403-5. PubMed ID: 14688038
[No Abstract] [Full Text] [Related]
9. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
Sharma A; Khuller GK; Sharma S
Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
[TBL] [Abstract][Full Text] [Related]
10. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.
Clements JM; Beckett RP; Brown A; Catlin G; Lobell M; Palan S; Thomas W; Whittaker M; Wood S; Salama S; Baker PJ; Rodgers HF; Barynin V; Rice DW; Hunter MG
Antimicrob Agents Chemother; 2001 Feb; 45(2):563-70. PubMed ID: 11158755
[TBL] [Abstract][Full Text] [Related]
12. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
[TBL] [Abstract][Full Text] [Related]
13. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy.
Kalita A; Verma I; Khuller GK
J Infect Dis; 2004 Oct; 190(8):1476-80. PubMed ID: 15378441
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
Kaushik A; Ammerman NC; Tasneen R; Story-Roller E; Dooley KE; Dorman SE; Nuermberger EL; Lamichhane G
J Antimicrob Chemother; 2017 Aug; 72(8):2320-2325. PubMed ID: 28575382
[TBL] [Abstract][Full Text] [Related]
15. Novel peptidomimetic peptide deformylase (PDF) inhibitors of Mycobacterium tuberculosis.
Gokhale KM; Telvekar VN
Chem Biol Drug Des; 2021 Jan; 97(1):148-156. PubMed ID: 32745362
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
17. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
18. Sulfamethoxazole enhances the antimycobacterial activity of rifampicin.
Macingwana L; Baker B; Ngwane AH; Harper C; Cotton MF; Hesseling A; Diacon AH; van Helden P; Wiid I
J Antimicrob Chemother; 2012 Dec; 67(12):2908-11. PubMed ID: 22875849
[TBL] [Abstract][Full Text] [Related]
19. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Bhusal Y; Shiohira CM; Yamane N
Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
[TBL] [Abstract][Full Text] [Related]
20. The carboxy-terminal end of the peptide deformylase from Mycobacterium tuberculosis is indispensable for its enzymatic activity.
Saxena R; Chakraborti PK
Biochem Biophys Res Commun; 2005 Jul; 332(2):418-25. PubMed ID: 15896710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
